Title Adjunctive mood stabilizer treatment for hospitalized schizophrenia patients : Asia psychotropic prescripton study

Recent studies indicate relatively high international rates of adjunctive psychotropic medication, including mood stabilizers, for patients with schizophrenia. Since such treatments are little studied in Asia, we examined the frequency of mood-stabilizer use and its clinical correlates among hospitalized Asian patients diagnosed with schizophrenia in 2001–2008. We evaluated usage rates of mood stabilizers with antipsychotic drugs, and associated factors, for in-patients diagnosed with DSM-IV schizophrenia in 2001, 2004 and 2008 in nine Asian regions : China, Hong Kong, India, Korea, Japan, Malaysia, Taiwan, Thailand, and Singapore. Overall, mood stabilizers were given to 20.4% (n=1377/6761) of hospitalized schizophrenia patients, with increased usage over time. Mood-stabilizer use was significantly and independently associated in multivariate logistic modeling with : aggressive behaviour, disorganized speech, year sampled (2008 vs. earlier), multiple hospitalizations, less negative symptoms, younger age, with regional variation (Japan, Hong Kong, Singapore>Taiwan or China). Co-prescription of adjunctive mood stabilizers with antipsychotics for hospitalized Asian schizophrenia patients increased over the past decade, and was associated with specific clinical characteristics. This practice parallels findings in other countries and illustrates ongoing tension between evidence-based practice vs. individualized, empirical treatment of psychotic disorders. Received 11 August 2010 ; Reviewed 11 October 2010 ; Revised 18 March 2011 ; Accepted 21 March 2011 ; First published online 18 April 2011

[1]  S. Leucht,et al.  Valproate for schizophrenia. , 2016, The Cochrane database of systematic reviews.

[2]  D. Kelly,et al.  The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements , 2012 .

[3]  G. Fitzmaurice,et al.  Use of mood stabilizers for hospitalized psychotic and bipolar disorder patients , 2011, International clinical psychopharmacology.

[4]  R. Baldessarini,et al.  International consensus study of antipsychotic dosing. , 2010, The American journal of psychiatry.

[5]  R. Baldessarini,et al.  Changes in medication practices for hospitalized psychiatric patients: 2009 versus 2004 , 2010, Human psychopharmacology.

[6]  Hannah F Jones,et al.  Antiepileptics for aggression and associated impulsivity. , 2010, The Cochrane database of systematic reviews.

[7]  L. Citrome Adjunctive lithium and anticonvulsants for the treatment of schizophrenia: what is the evidence? , 2009, Expert review of neurotherapeutics.

[8]  O. Andreassen,et al.  Beliefs about medications: measurement and relationship to adherence in patients with severe mental disorders , 2009, Acta psychiatrica Scandinavica.

[9]  M. Valenstein,et al.  Long-term antipsychotic polypharmacy in the VA health system: patient characteristics and treatment patterns. , 2007, Psychiatric services.

[10]  J. Mallinger,et al.  Racial differences in the use of adjunctive psychotropic medications for patients with schizophrenia. , 2007, The journal of mental health policy and economics.

[11]  P. Gorwood Meeting everyday challenges: Antipsychotic therapy in the real world , 2006, European Neuropsychopharmacology.

[12]  H. Meltzer,et al.  Valproic acid potentiates both typical and atypical antipsychotic-induced prefrontal cortical dopamine release , 2005, Brain Research.

[13]  S. Leucht,et al.  Valproate as an adjunct to antipsychotics for schizophrenia: a systematic review of randomized trials , 2004, Schizophrenia Research.

[14]  S. Heckers,et al.  Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia. , 2004, British journal of clinical pharmacology.

[15]  T. Si,et al.  High dose antipsychotic use in schizophrenia: findings of the REAP (research on east Asia psychotropic prescriptions) study. , 2004, Pharmacopsychiatry.

[16]  S. Stahl Anticonvulsants as mood stabilizers and adjuncts to antipsychotics: valproate, lamotrigine, carbamazepine, and oxcarbazepine and actions at voltage-gated sodium channels. , 2004, The Journal of clinical psychiatry.

[17]  F. Trémeau,et al.  A Study of the Safety, Efficacy, and Tolerability of Switching From the Standard Delayed Release Preparation of Divalproex Sodium to the Extended Release Formulation in Patients With Schizophrenia , 2004, Journal of clinical psychopharmacology.

[18]  L. Kochan,et al.  GABA and Schizophrenia: A Review of Basic Science and Clinical Studies , 2003, Journal of clinical psychopharmacology.

[19]  R. Buchanan,et al.  Relationship of the use of adjunctive pharmacological agents to symptoms and level of function in schizophrenia. , 2002, The American journal of psychiatry.

[20]  G. Simpson,et al.  Psychopharmacology: rational and irrational polypharmacy. , 2001, Psychiatric services.

[21]  John E. Cooper,et al.  Diagnostic and Statistical Manual of Mental Disorders (4th edn, text revision) (DSM-IV-TR) , 2001, British Journal of Psychiatry.

[22]  G. Winterer,et al.  Valproate and the symptomatic treatment of schizophrenia spectrum patients. , 2000, Pharmacopsychiatry.

[23]  J. Levine,et al.  Changes in use of valproate and other mood stabilizers for patients with schizophrenia from 1994 to 1998. , 2000, Psychiatric services.

[24]  J. Guelfi,et al.  Guidelines for depot antipsychotic treatment in schizophrenia , 1998, European Neuropsychopharmacology.

[25]  C. Galletly,et al.  Antipsychotic Drug Doses and Adjunctive Drugs in the Outpatient Treatment of Schizophrenia , 1997, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

[26]  A. Llerena,et al.  Patterns of drug treatment of schizophrenic patients in Estonia, Spain and Sweden. , 1995, British journal of clinical pharmacology.

[27]  T. Terao,et al.  Lithium addition to neuroleptic treatment in chronic schizophrenia: a randomized, double‐blind, placebo‐controlled, cross‐over study , 1995, Acta psychiatrica Scandinavica.

[28]  W. Wilson Addition of lithium to haloperidol in non-affective, antipsychotic non-responsive schizophrenia: a double blind, placebo controlled, parallel design clinical trial , 1993, Psychopharmacology.

[29]  E. Larkin,et al.  Lithium carbonate in chronic schizophrenia — a brief trial of lithium carbonate added to neuroleptics for treatment of resistant schizophrenic patients , 1991, Acta psychiatrica Scandinavica.

[30]  H. Emrich,et al.  Carbamazepine as an adjunct of antipsychotic therapy , 1987, Psychiatry Research.

[31]  R. Conley,et al.  Adjunct Divalproex or Lithium to Clozapine in Treatment-Resistant Schizophrenia , 2006, Psychiatric Quarterly.

[32]  J. Haro,et al.  The SOHO (Schizophrenia Outpatient Health Outcome) Study , 2006, CNS drugs.

[33]  R. Petty,et al.  Valproate for hostility in schizophrenia patients. , 2004, The Journal of clinical psychiatry.

[34]  J. Guelfi,et al.  Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy. , 1998, European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology.

[35]  J. van os,et al.  Do we need a European consensus on the use of antipsychotic medication? , 1996, European Psychiatry.

[36]  G. Braemer International statistical classification of diseases and related health problems. Tenth revision. , 1988, World health statistics quarterly. Rapport trimestriel de statistiques sanitaires mondiales.